The Board advised that patients no longer be enrolled in the aprotinin group owing to an
increased risk of death. Massive bleeding rates tended to be lower among patients receiving …

The aprotinin story began in 1987, when investigators reported that the use of the drug in
patients undergoing repeat open-heart surgery decreased the need for blood transfusion by …

Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize
bleeding and to reduce exposure to blood products. We sought to determine whether …

Aprotinin is a serine protease inhibitor with antithrombotic, antifibrinolytic, and
antiinflammatory effects. It is effective in reducing bleeding and the need for blood …

Excessive postoperative bleeding during cardiac surgery calls for transfusions of allogeneic
blood products, and up to 5% of patients undergoing coronary artery bypass grafting and …

Background The majority of patients undergoing surgical treatment for ST-elevation
myocardial infarction receive antifibrinolytic therapy to limit blood loss. This approach …

OBJECTIVE: Meta-analysis of small, randomized, placebo-controlled trials demonstrated
efficacy and safety of aprotinin. After highly publicized retrospective studies and the early …

Cardiac surgery is associated with a systemic inflammatory response and systemic
coagulopathy, which can result in significant organ dysfunction and bleeding. Aprotinin, a …

Background: Aprotinin is the only Food and Drug Administration-approved agent to reduce
haemorrhage related to cardiac surgery and its safety and efficacy has been extensively …

Background To compare the effect of aprotinin with the effect of lysine analogues
(tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients …